comparemela.com

Latest Breaking News On - International prognostic scoring system - Page 4 : comparemela.com

Roivant Sciences to Discontinue RVT-2001 Development in Myelodysplastic Syndrome

Investigation of RVT-2001 will be discontinued following an insufficient display of benefit in patients with myelodysplastic syndrome.

Matt glineRoivant sciencesInternational prognostic scoring systemLower risk mdsMyelodysplastic syndromeRvt 2001

All-Oral Therapy Promising in Higher-Risk MDS, CMML

In small trial, overall response rate was 95%

United statesMike bassettSarit assoulineGuillermo garcia maneroAssoulines decitabineHospital at mcgill universityInternational working groupUniversity of texas md anderson cancer centerInternational prognostic scoring systemCancer centerJewish general hospitalMcgill university

MDS Research Expands Treatment Options Across Disease Subsets

Talha Badar, MBBS, MD, discusses myelodysplastic syndrome risk stratification and the FDA approval of luspatercept for patients with this disease.

United statesTalha badarInternational prognostic scoring systemMayo clinicRevised international prognostic scoring systemMyeloproliferative neoplasmsFda approval

Oral HMAs May Provide Safer and More Effective Treatment Options for MDS

Guillermo Garcia-Manero, MD, spotlights the evolution of oral azacitidine- and decitabine-based regimens for MDS.

United statesGuillermo garcia maneroTranslational researchInternational prognostic scoring systemDivision of cancer medicineUniversity of texas md anderson cancer centerDepartment of leukemiaFaculty senateMyelodysplastic syndromesCancer medicineCancer centerRevised international prognostic scoring systemMyeloproliferative neoplasmsOral regimensDecitabine plus cedazuridineAzacitidine plus cedazuridine

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

Amer Zeidan, MBBS, MHS, presents data from the IMerge phase 3 study on the efficacy of imetelstat in achieving red blood cell transfusion independence across different risk subgroups in patients with lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis-stimulating agents.

San diegoUnited statesSamer zeidanInternational prognostic scoring systemAchieving red blood cell transfusion independenceDifferent risk subgroupsLower risk myelodysplastic syndromesErythropoiesis stimulating agentsPartnership withMyelodysplastic syndromeImerge studyImerge trialImerge phase 3 studyLower risk mdsLower risk myelodysplastic syndromeRed blood cell transfusion independence

vimarsana © 2020. All Rights Reserved.